Dr. Naidoo Discusses Biomarker Testing for Checkpoint Inhibitors

Jarushka Naidoo, MD, BCh
Published: Sunday, Mar 24, 2019



Jarushka Naidoo, MBBCh, assistant professor of oncology, John Hopkins University, discusses the application of biomarker testing for use of checkpoint inhibitors in patients with cancer.

Nadioo says that there are agents are now approved in 13 or more different cancer types; however, biomarker testing depends on the cancer type and at which stage the patient is at in their disease. PD-L1 testing via immunohistochemistry is one of the most extensive biomarker tests to be done.

Different companies utilize different antibodies to test for this particular biomarker, says Naidoo. For instance, different cell populations can be used to define PD-L1 activity, she concludes. 

<<< 2019 NCCN Annual Meeting


Jarushka Naidoo, MBBCh, assistant professor of oncology, John Hopkins University, discusses the application of biomarker testing for use of checkpoint inhibitors in patients with cancer.

Nadioo says that there are agents are now approved in 13 or more different cancer types; however, biomarker testing depends on the cancer type and at which stage the patient is at in their disease. PD-L1 testing via immunohistochemistry is one of the most extensive biomarker tests to be done.

Different companies utilize different antibodies to test for this particular biomarker, says Naidoo. For instance, different cell populations can be used to define PD-L1 activity, she concludes. 

<<< 2019 NCCN Annual Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x